Proteomics in cancer vaccine development.
Proteomics is a new scientific field aimed at the large-scale characterization of the protein constituents of biologic systems. It facilitates comparisons between different protein preparations by searching for minute differences in their protein expression repertoires and the patterns of their post-translational modifications. These attributes make proteomics perfectly suited for searching for proteins and peptides expressed exclusively or preferentially in cancer cells as candidates for cancer vaccines. The main proteomics technologies include 2D polyacrylamide gel electrophoresis, multidimensional high-performance liquid chromatography, mass spectrometry and protein arrays. Proteomics technologies used to analyze cancer culture cells, fresh tumor specimens, human leukocyte antigen peptides, serum and serum antibodies (serologic proteomics) have successfully identified tumor markers. Turning the potential vaccine candidates identified by proteomics technologies into clinical treatments awaits demonstration.
Shoshan
Stacy H
SH
Technion-Israel Institute of Technology, Department of Biology, Haifa 32000, Israel. sshoshan@tx.technion.ac.il
Admon
Arie
A
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology / Q000302:isolation & purification; D019496:Cancer Vaccines / Q000138:chemical synthesis; D015180:Electrophoresis, Gel, Two-Dimensional; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000628:therapy*; D040081:Protein Array Analysis; D014176:Protein Biosynthesis; D040901:Proteomics; D012270:Ribosomes / Q000378:metabolism; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D006680:HLA Antigens